Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA

◆ ◆ The Wire takeaway

You can now anticipate faster regulatory pathways in multi-cancer detection diagnostics due to FDA's breakthrough device designation. This opening means your early-stage diagnostic product can benefit from accelerated approval timing.